E. Mellon

The Lancet Oncology · 2007–2016

A researcher in the Science corpus: 2 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from E. Mellon's perspective

Ordered by how strongly the researchers E. Mellon trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Grey literature in meta-analyses of randomized trials of health care interventions. (Cochrane Database of Systematic Reviews)
  2. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. (Journal of Clinical Oncology)
  3. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. (Journal of the American Medical Association (JAMA))
  4. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. (New England Journal of Medicine)
  5. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (British medical journal)
  6. An Algorithm for Least-Squares Estimation of Nonlinear Parameters
  7. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced… (Annals of Oncology)
  8. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. (Journal of magnetic resonance (San Diego, Calif. 1997 : Print))
  9. Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement (Annals of Surgical Oncology)
  10. Advanced pancreatic carcinoma: current treatment and future challenges (Nature Reviews Clinical Oncology)

Their papers